noxa

Potent and selective NADPH oxidase 1 (NOX1) inhibitor (IC50 = 20 nM). Exhibits selectivity for NOX1 over NOX2, NOX4, NOX5 and xanthine oxidase. Inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. Attenuates VEGF-induced human pulmonary

Noxa A BH3, a bioactive peptide, encompasses the BH3 domain of the Noxa protein.

r8-Gly-Noxa A BH3 is a biologically active, cell-permeable peptide comprising amino acid residues 17 to 36 from the BH3 (death) domain of Noxa A, modified by eight D-Arginine residues and a Glycine linker at its amino terminus.

Noxa B BH3, a biologically active peptide encompassing the BH3 domain of the Noxa protein, displays targeted biological activity.

NoxA1ds acetate is a potent and selective NADPH oxidase 1 (NOX1) inhibitor (IC50 : 20 nM). Exhibits selectivity for NOX1 over NOX2, NOX4, NOX5 and xanthine oxidase. Inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. Attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro.

NoxA1ds TFA is a potent and selective inhibitor of NADPH oxidase 1 (NOX1) with an inhibition concentration (IC50) of 20 nM, showing selectivity over NOX2, NOX4, NOX5, and xanthine oxidase. It effectively inhibits NOX1-derived O2- production in HT-29 human colon cancer cells and attenuates VEGF-induced migration of human pulmonary artery endothelial cells under hypoxic conditions in vitro.

NoxaBH3, a cysteine-based cross-linked peptide, exhibits enhanced cell permeability and greater inhibitory efficacy against Mcl-1. It binds to the endogenous CXCR4 ligand, resulting in the formation of a ubiquitin-NoxaBH3 conjugate that is subsequently delivered to cancer cells [1].